{
    "doi": "https://doi.org/10.1182/blood.V120.21.599.599",
    "article_title": "Refinement in Patient Selection to Reduce Treatment-Related Mortality From Stem Cell Transplantation in Amyloidosis ",
    "article_date": "November 16, 2012",
    "session_type": "731. Clinical Allogeneic and Autologous Transplantation - Results: Autologous Transplant for Myeloma and Amyloidosis",
    "abstract_text": "Abstract 599 Purpose: This study was undertaken to develop selection guidelines for transplant centers to determine eligibility for stem cell transplantation in patients with light chain amyloidosis. Patients and Methods: Patients with biopsy-confirmed immunoglobulin light chain amyloidosis who underwent stem cell transplantation between March 8, 1996, and December 31, 2011, were reviewed in 2 cohorts: those who underwent transplantation between March 8, 1996, and June 30, 2009, and those who underwent transplantation between July 1, 2009, and December 31, 2011 ( table 1 ). A second comparison was undertaken among patients who died before posttransplant day 100 to determine features predictive of early death ( table 2 ). Results: A total of 499 patients were identified, 410 in the earlier group and 89 in the later group. After July 1, 2009, significantly fewer transplant recipients had Mayo stage III cardiac involvement. Mortality before posttransplant day 100 was 10.5% (43/410) in the earlier group and 1.1% (1/89) in the later group. In the earlier group, one-quarter of transplant recipients with N-terminal pro-brain natriuretic peptide (NT-proBNP) levels higher than 5,000 pg/mL died by 10.3 months ( fig 1 , left). When the serum troponin T level was > 0.06 ng/mL, 25% died at 3.7 months ( fig 2 , right). Conclusion: The Mayo staging system is highly predictive for overall survival but not useful for selecting transplant recipients. Patients with serum troponin T levels higher than 0.06 ng/mL or NT-proBNP levels >5,000 pg/mL (not on dialysis) should not be considered acceptable candidates for stem cell transplantation because of unacceptable early mortality. Table 1. Comparison of Patients Receiving Transplants Before and After July 1, 2009 Characteristic Compared . Transplant Before 7/1/09 (n=410) . Transplant After 7/1/09 (n=89) . P Value . Mayo stage, No. (%) a    .02 I 104/281 (37) 44/85 (52)  II 115/281 (41) 31/85 (36)  III 62/281 (22) 10/85 (12)  Male, No. (%) 245 (60) 54 (61) .78 Heart involved, No. (%) 208 (51) 31 (35) .006 Kidney involved, No. (%) 285 (70) 61 (69) .90 Albumin, median (IQR), g/dL 2.7 (1.9\u20133.3) 2.6 (2.1\u20133.3) .43 Creatinine, median (IQR, mg/dL) 1.8 (0.9\u20131.3) 1.0 (0.8\u20131.2) .002  (10%>1.8) (10%>1.5)  Marrow PC, median (IQR), % 7 (3\u201313) 8.5 (4\u201314) .04 Septal thickness, median (IQR), mm 12 (10\u201314) 11 (10\u201314) .08 EF, median (IQR), % 65 (60\u201369) 64 (61\u201367) .31 Age, median (IQR), y 57.5 (51\u201363) 58.4 (54\u201363) .18 Troponin T, median (IQR), ng/mL 0.01 (0.01\u20130.03) 0.01 (0.01\u20130.02) .1 iFLC, median (IQR), mg/dL 15.5 (7.3\u201337.4) 11.4 (5.8\u201329.8) .05 NT-proBNP, median (IQR), pg/mL 662 (166\u20132,766) 322 (125\u20131,100) .02  (10%>6,537) (10%>4,023)  Characteristic Compared . Transplant Before 7/1/09 (n=410) . Transplant After 7/1/09 (n=89) . P Value . Mayo stage, No. (%) a    .02 I 104/281 (37) 44/85 (52)  II 115/281 (41) 31/85 (36)  III 62/281 (22) 10/85 (12)  Male, No. (%) 245 (60) 54 (61) .78 Heart involved, No. (%) 208 (51) 31 (35) .006 Kidney involved, No. (%) 285 (70) 61 (69) .90 Albumin, median (IQR), g/dL 2.7 (1.9\u20133.3) 2.6 (2.1\u20133.3) .43 Creatinine, median (IQR, mg/dL) 1.8 (0.9\u20131.3) 1.0 (0.8\u20131.2) .002  (10%>1.8) (10%>1.5)  Marrow PC, median (IQR), % 7 (3\u201313) 8.5 (4\u201314) .04 Septal thickness, median (IQR), mm 12 (10\u201314) 11 (10\u201314) .08 EF, median (IQR), % 65 (60\u201369) 64 (61\u201367) .31 Age, median (IQR), y 57.5 (51\u201363) 58.4 (54\u201363) .18 Troponin T, median (IQR), ng/mL 0.01 (0.01\u20130.03) 0.01 (0.01\u20130.02) .1 iFLC, median (IQR), mg/dL 15.5 (7.3\u201337.4) 11.4 (5.8\u201329.8) .05 NT-proBNP, median (IQR), pg/mL 662 (166\u20132,766) 322 (125\u20131,100) .02  (10%>6,537) (10%>4,023)  View Large Table 2. Survival (Before/After Posttransplant Day 100) in 410 Patients Who Received Transplants Before July 1, 2009 Characteristic Compared . Died Before Day 100 (n=43) . Survived After Day 100 (n=367) . P Value . Mayo stage, No. (%) a    .002 I 4/28 (14) 100/253 (40)  II 13/28 (46) 102/253 (40)  III 11/28 (39) 51/253 (20)  Kidney involved, No. (%) 33 (77) 252 (69) .30 Heart involved, No. (%) 32 (74) 191 (52) <.001 Albumin, median (IQR), g/dL 2.3 (1.7\u20133.0) 2.7 (2.0\u20133.3) .02 Creatinine, median (IQR), mg/dL 1.2 (1.0\u20131.7) 1.1 (0.9\u20131.3) .001 Marrow PC, median (IQR), % 6 (4\u201312) 7 (3\u201313) .90 Septal thickness, median (IQR), mm 14 (12\u201316) 12 (10\u201314) <.001 EF, median (IQR), % 66 (56\u201370) 65 (60\u201369) .97 Age, median (IQR), y 56 (49\u201365) 57 (51\u201362) .60 Troponin T, median (IQR), ng/mL 0.03 (0.01\u20130.08) 0.01 (0.01\u20130.06) <.001  (10%>0.125) (10%>0.05)  iFLC, median (IQR), mg/dL 21.3 (15\u201343.7) 15.2 (6.4\u201336.5) .004 NT-proBNP, median (IQR), pg/mL 2,752 (666\u20134,645) 600 (170\u20131,969) <.001  (10%>10,753) (10%>5,383)  Characteristic Compared . Died Before Day 100 (n=43) . Survived After Day 100 (n=367) . P Value . Mayo stage, No. (%) a    .002 I 4/28 (14) 100/253 (40)  II 13/28 (46) 102/253 (40)  III 11/28 (39) 51/253 (20)  Kidney involved, No. (%) 33 (77) 252 (69) .30 Heart involved, No. (%) 32 (74) 191 (52) <.001 Albumin, median (IQR), g/dL 2.3 (1.7\u20133.0) 2.7 (2.0\u20133.3) .02 Creatinine, median (IQR), mg/dL 1.2 (1.0\u20131.7) 1.1 (0.9\u20131.3) .001 Marrow PC, median (IQR), % 6 (4\u201312) 7 (3\u201313) .90 Septal thickness, median (IQR), mm 14 (12\u201316) 12 (10\u201314) <.001 EF, median (IQR), % 66 (56\u201370) 65 (60\u201369) .97 Age, median (IQR), y 56 (49\u201365) 57 (51\u201362) .60 Troponin T, median (IQR), ng/mL 0.03 (0.01\u20130.08) 0.01 (0.01\u20130.06) <.001  (10%>0.125) (10%>0.05)  iFLC, median (IQR), mg/dL 21.3 (15\u201343.7) 15.2 (6.4\u201336.5) .004 NT-proBNP, median (IQR), pg/mL 2,752 (666\u20134,645) 600 (170\u20131,969) <.001  (10%>10,753) (10%>5,383)  View Large View large Download slide View large Download slide Close modal View large Download slide View large Download slide Close modal Disclosures: No relevant conflicts of interest to declare.",
    "topics": [
        "amyloidosis",
        "hematopoietic stem cell transplantation",
        "nt-probnp",
        "transplantation",
        "albumins",
        "creatinine",
        "primary amyloidosis",
        "biopsy",
        "cardiovascular findings",
        "dialysis procedure"
    ],
    "author_names": [
        "Morie A Gertz",
        "Martha Q Lacy, MD",
        "Angela Dispenzieri, MD",
        "Shaji K. Kumar, MD",
        "David Dingli, M.D., Ph.D.",
        "Nelson Leung, MD",
        "William J Hogan, MBBCh",
        "Francis K Buadi, M.D.",
        "Suzanne R Hayman, MD"
    ],
    "author_dict_list": [
        {
            "author_name": "Morie A Gertz",
            "author_affiliations": [
                "Division of Hematology, Mayo Clinic, Rochester, MN, USA, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Martha Q Lacy, MD",
            "author_affiliations": [
                "Division of Hematology, Mayo Clinic, Rochester, MN, USA, "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Angela Dispenzieri, MD",
            "author_affiliations": [
                "Division of Hematology, Mayo Clinic, Rochester, MN, USA, "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Shaji K. Kumar, MD",
            "author_affiliations": [
                "Division of Hematology, Mayo Clinic, Rochester, MN, USA, "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "David Dingli, M.D., Ph.D.",
            "author_affiliations": [
                "Division of Hematology, Mayo Clinic, Rochester, MN, USA, "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Nelson Leung, MD",
            "author_affiliations": [
                "Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA"
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "William J Hogan, MBBCh",
            "author_affiliations": [
                "Division of Hematology, Mayo Clinic, Rochester, MN, USA, "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francis K Buadi, M.D.",
            "author_affiliations": [
                "Division of Hematology, Mayo Clinic, Rochester, MN, USA, "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Suzanne R Hayman, MD",
            "author_affiliations": [
                "Division of Hematology, Mayo Clinic, Rochester, MN, USA, "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-22T18:45:23",
    "is_scraped": "1"
}